drugset / Trial / NCT00160992
Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients
Phase 1
Suspended
6 enrolled
University of Lausanne Hospitals
Barletta Foundation · collabFond'action contre le cancer · collabNCCR (National Center of Competence in Resaerch, Switzerland) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Patients with advanced stage melanoma who underwent vaccination with the Melan-A/MART-1 peptide and who display detectable levels of Melan-A specific CD8+ T cells in peripheral blood are eligible for this trial. After collecting and freezing of these tumor specific T cells via apheresis, patients undergo a single cycle of immunosuppressive chemotherapy. 3 days after, cells are reinfused and peptide vaccination continued. The aim of this immunotherapy protocol is to boost tumor specific T cells during the immune recovery period in order to reinforce the patients' immune response against the tumor.
Timeline
- Start
- 2004-07
- Primary completion
- —
- Completion
- 2005-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Melan-A analog peptide | Peptide | — | — |